Demonstrating First-in-Human Clinical Translation of Circular RNA Therapeutics in Ischemic Disease
- Validate circular RNA as a clinically viable therapeutic modality by sharing global first-in-human dosing experience and early clinical insights from ischemic disease programs
- De-risk indication and modality selection by translating preclinical durability, expression, and safety data into real-world clinical decision-making frameworks
- Inform next-generation RNA development strategies by extracting early lessons on dosing, delivery, and trial design from one of the field’s first clinical programs